Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/11/21
End: 12/09/21
Due: 12/09/22
Phase: N/A
Priority: Normal
Start: 06/06/18
End: 07/07/19
Due: 07/07/20
Phase: N/A
Priority: Normal
Start: 02/15/24
End: 08/18/24
Due: 08/18/25
Phase: N/A
Priority: Normal
Start: 02/28/22
End: 02/15/25
Due: 02/15/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Mass Balance Study of NV-5138 in Healthy Male Subjects. | NCT05152680 | Navitor Pharmaceuticals, Inc. | user2@example.com | None | 2021-11-11 | 2021-12-09 | 2022-12-09 | - | - | 2025-07-14 |
| Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression | NCT03606395 | Navitor Pharmaceuticals, Inc. | user2@example.com | None | 2018-06-06 | 2019-07-07 | 2020-07-07 | - | - | 2025-07-14 |
| Open-Label of SPN-820 in Adults With Major Depressive Disorder | NCT06235905 | Navitor Pharmaceuticals, Inc. | user2@example.com | None | 2024-02-15 | 2024-08-18 | 2025-08-18 | - | - | 2025-07-14 |
| Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression | NCT05066672 | Navitor Pharmaceuticals, Inc. | user2@example.com | None | 2022-02-28 | 2025-02-15 | 2026-02-15 | - | - | 2025-07-14 |